Compare DSGR & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSGR | KLRA |
|---|---|---|
| Founded | 1952 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 1995 | 2026 |
| Metric | DSGR | KLRA |
|---|---|---|
| Price | $34.96 | $10.88 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $35.00 | N/A |
| AVG Volume (30 Days) | 186.0K | ★ 976.4K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 212.50 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,980,023,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $184.11 | ★ N/A |
| Revenue Growth | ★ 9.75 | N/A |
| 52 Week Low | $19.02 | $10.83 |
| 52 Week High | $35.06 | $23.82 |
| Indicator | DSGR | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 74.35 | 27.45 |
| Support Level | $34.63 | N/A |
| Resistance Level | $35.06 | $19.15 |
| Average True Range (ATR) | 0.07 | 0.86 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 88.89 | 1.53 |
Distribution Solutions Group Inc is a specialty distribution company providing value-added distribution solutions to the maintenance, repair and operations (MRO), original equipment manufacturer (OEM) and industrial technology markets. The company operates through four reportable segments: Lawson, TestEquity, Gexpro Services and Canada Branch Division. Lawson distributes specialty products and services to the industrial, commercial, institutional and government MRO marketplace. TestEquity, which generates maximum revenue, distributes test and measurement equipment and solutions, industrial and electronic production supplies and vendor managed inventory programs. Gexpro Services is a supply chain solutions provider. The company generates majority of its revenue from United States.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.